Cancer Stem Cells Market (2026 - 2033 )

Cancer Stem Cells Market Summary

The global cancer stem cells market size was valued at USD 3.5 billion in 2025 and is projected to grow from USD 3.8 billion in 2026 to USD 7.3 billion by 2033, at a CAGR of 9.8% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of around 36.0% in 2025. The growing prevalence of cancer, increased R&D activity, and the adoption of stem cell therapies are among the major factors driving the market.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Currently, oncology therapeutics have entered a new era, with conventional therapies such as radiotherapy, chemotherapy, & surgeries on one side and stem cell therapies on the other. Over the past few years, stem cells have been successfully used for immune reconstitution and blood replenishment following tumor development or treatment. Furthermore, these cells have gained significant attention among healthcare entities for their use as tools to deliver anti-cancer agents and promote tissue regeneration. A considerable number of entities have reported positive outcomes of using this mode of tumor treatment. While this therapy is receiving huge success in clinical oncology, a substantial number of published studies have mentioned cancer as a “Cancer Stem Cell (CSC) disorder.” Due to the introduction of this novel concept, an enormous potential for anti-CSC therapeutics has been created.

This approach enables a comprehensive investigation of essential and poorly understood clinical events in tumor initiation, propagation, relapse, and metastasis. This is considered one of the major factors driving interest in the cancer stem cell model. Evidence exists that supports the existence of cancer stem cells and their role in conferring drug resistance. This further allows the generation of novel targets to overcome therapeutic resistance by controlling the regulation of these cells. Hence, CSCs, as potential therapeutic targets, enable the development of therapies that effectively combat tumor progression.

There has been a constant rise in the number of cancer cases and cancer-related deaths globally over the years. For instance, according to the World Health Organization (WHO), in February 2024, an estimated 20 million new cancer cases and 9.7 million cancer-related deaths occurred globally in 2022, and it is the leading cause of death worldwide. Thus, it has become very important to find an efficient treatment to regulate cancer and improve the standard of living of cancer patients. This has increased the R&D activities in the market.

Furthermore, government agencies and research organizations are actively supporting advances in stem cell-based cancer research. For instance, in October 2024, the California Institute for Regenerative Medicine (CIRM) awarded approximately USD 27 million to establish six Shared Resources Laboratories across California. The funding is intended to strengthen stem cell and gene therapy research infrastructure, accelerate translational research, and support the development of next-generation regenerative medicine therapies for cancer and other serious diseases. However, challenges related to manufacturing complexity, regulatory requirements, and the commercialization of stem cell-based therapies are expected to restrain market growth to some extent.

Analyst Perspective

The CSC market is driven by the increasing focus on developing targeted therapies to address tumor initiation, metastasis, recurrence, and treatment resistance. Growing evidence highlighting the critical role of cancer stem cells in disease progression and relapse has accelerated research into novel CSC-targeted therapeutics, biomarkers, and regenerative medicine approaches. The rising global cancer burden, expanding clinical trial activity, and increasing investments by pharmaceutical companies, biotechnology firms, and government research organizations are supporting the development of next-generation stem cell-based and precision oncology therapies. Continued advancements in molecular biology, gene editing, and cell analysis technologies are further expected to create significant opportunities for innovation and market expansion.

Mode of Action Insights

The targeted cancer stem cells (CSCs) segment dominated the market with around 60.0% share in 2025. This model incorporates targeted CSCs using monoclonal antibodies, recombinant proteins, nanomaterials, and other natural compounds. Most commercially available drugs facilitate tumor shrinkage but do not target the root cause of tumor progression, which may further result in a relapse of tumor growth. Increasing research on CSC biology, key signaling pathways, microenvironment, and surface markers is enabling the development of agents that target these aspects of CSCs to control their regulation. Of these aspects, agents targeting key pathways accounted for a major share.

The stem cell usage against cancer segment is projected to grow steadily over the forecast period. This model deploys stem cells for tissue regeneration, immune reconstitution, and delivery of anti-cancer therapeutics. Stem cells have the unique ability to differentiate into various cell types, a capacity that can be harnessed to regenerate healthy tissues damaged by cancer or its treatments. The use of stem cells in combination with other anti-cancer agents offers a novel approach to combatting tumors and enhancing patient outcomes. As research continues to explore the therapeutic potential of stem cells in oncology, the demand for innovative stem cell-based cancer therapies is driving the expansion of the global market.

This segment is further divided into autologous and allogeneic cell treatments. Autologous treatments captured a significant share of the revenue market in 2025. Factors such as the advantages of autologous transplants, affordability, improved patient survival rates, and an increase in transplantation procedures are poised to contribute to the growth of the segment. However, it has been observed that many cell therapy companies are increasingly focusing on the development of allogeneic cellular therapy products.

Cancer Forms Insights

The breast cancer segment dominated the market, accounting for around 27.0% of global revenue in 2025, owing to its high prevalence and extensive research into cancer stem cell biology, targeted therapeutics, and precision oncology. According to the World Health Organization (WHO), approximately 2.3 million women were diagnosed with breast cancer in 2022, resulting in nearly 670,000 deaths worldwide. In addition, the American Cancer Society (ACS) estimated 287,850 new invasive breast cancer cases and approximately 43,250 breast cancer-related deaths in the U.S. in 2022. The growing understanding of the role of cancer stem cells in tumor initiation, metastasis, therapeutic resistance, and recurrence has accelerated the development of novel targeted therapies and biomarker-driven treatment strategies for breast cancer. Furthermore, stem cell-based regenerative approaches are being investigated to mitigate treatment-related cardiotoxicity, while lifestyle factors such as obesity, physical inactivity, unhealthy diets, and alcohol consumption continue to contribute to the rising disease burden, supporting demand for advanced therapeutic solutions.

The lung cancer segment is anticipated to register the fastest CAGR over the forecast period. The segment's growth is primarily driven by the high global incidence of lung cancer and increasing investments in targeted oncology research. According to the American Cancer Society, approximately 229,410 new lung cancer cases and 124,990 lung cancer-related deaths are expected in the U.S. in 2026. Growing research into cancer stem cell-targeted therapies and biomarker-based treatment approaches for non-small cell lung cancer (NSCLC) is further supporting market expansion. For instance, in July 2025, the U.S. FDA granted accelerated approval to sunvozertinib (Zegfrovy) for the treatment of adults with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations whose disease had progressed following platinum-based chemotherapy. The approval highlights the continued advancement of precision oncology and targeted cancer therapies, creating a favorable environment for the development of next-generation cancer stem cell-based treatment approaches.

Regional Insights

The North America cancer stem cells market dominated with the largest revenue share of around 36.0% in 2025. The regional leadership is primarily attributed to its advanced healthcare infrastructure, strong biotechnology ecosystem, high oncology research expenditure, and the presence of numerous pharmaceutical and research organizations actively developing stem cell- and cell-based cancer therapies. The high prevalence of cancers such as breast, blood, and lung cancer further supports market growth. According to the U.S. Cancer Statistics (USCS) released by the Centers for Disease Control and Prevention (CDC) in January 2026, approximately 1,851,238 new cancer cases were reported in the United States in 2022, while 613,349 cancer-related deaths were recorded in 2023. In addition, the presence of internationally recognized cancer centers and academic medical institutions that offer stem cell transplantation and conduct advanced oncology research continues to strengthen the region's market position.

To learn more about this report, Download Free Sample Report

U.S. Cancer Stem Cells Market Trends

The cancer stem cells market in the U.S. is driven by the country's robust biomedical research infrastructure, increasing investments in precision oncology, and growing clinical trial activity focused on cancer stem cell-targeted therapies. Strong government funding, the presence of leading biotechnology companies, and favorable regulatory support for innovative cancer treatments continue to accelerate the development and commercialization of advanced stem cell-based therapies.

Europe Cancer Stem Cells Market Trends

The cancer stem cells market in Europe is supported by its well-established healthcare systems, strong emphasis on oncology research, and growing investments in regenerative medicine and precision oncology. Government funding programs, collaborative research initiatives, and the growing adoption of personalized cancer treatment approaches continue to support regional market growth.

The UK cancer stem cells market is expected to grow over the forecast period, driven by increasing adoption of personalized oncology approaches and strong support from the National Health Service (NHS) and leading academic research institutions. Continued investments in translational research and biomarker-driven therapies are expected to accelerate the development of cancer stem cell-targeted treatments and improve clinical outcomes.

Asia Pacific Cancer Stem Cells Market Trends

The cancer stem cell market in Asia Pacific is anticipated to register the fastest growth during the forecast period, primarily due to the rapidly increasing cancer burden, expanding healthcare infrastructure, and rising investments in oncology research. According to GLOBOCAN 2022, approximately 4.82 million new cancer cases were diagnosed in China, highlighting the substantial need for advanced cancer treatment approaches. Furthermore, increasing government funding, growing biotechnology investments, and expanding research focused on cancer stem cells across China, Japan, South Korea, and India are expected to support regional market expansion. For instance, in November 2024, researchers at Hebei University in China developed a membrane-cloaked nanodrug designed to selectively target and eliminate therapeutic stress-escaped cancer stem cells. The study demonstrated enhanced cancer stem cell targeting and improved anti-tumor efficacy, highlighting continued advancements in nanomedicine-based CSC therapies.

The China cancer stem cells market accounted for the largest share of the Asia Pacific in 2025. The country's large patient population, rising cancer incidence, expanding biotechnology sector, and substantial government support for stem cell and oncology research continue to drive market growth. Increasing investments in translational medicine and precision oncology are further accelerating the development of innovative cancer stem cell therapies.

Key Cancer Stem Cells Companies Insights

The global cancer stem cells market is characterized by the presence of several established biotechnology, pharmaceutical, and life sciences companies, including Thermo Fisher Scientific, Inc., AbbVie Inc., Merck KGaA, Bionomics, and Lonza. Market participants are actively expanding their oncology and regenerative medicine portfolios through strategic collaborations, acquisitions, research partnerships, and product development initiatives to strengthen their competitive position. For instance, in March 2025, AstraZeneca announced the acquisition of EsoBiotec, a biotechnology company specializing in in vivo cell therapies. The acquisition strengthens AstraZeneca's cell therapy portfolio by incorporating EsoBiotec's ENaBL platform, which enables immune cells to be genetically programmed directly within the patient's body to specialize in eliminating cancer cells, supporting the advancement of next-generation cancer therapies.

Key Cancer Stem Cells Company Insights

Some of the prominent players in the global cancer stem cells market include:

• STEMCELL Technologies Inc. is a biotechnology company that specializes in developing cell culture media, instruments, cell separation products, and other reagents for use in stem cell, immunology, cancer, regenerative medicine, and cellular therapy research.

Key Cancer Stem Cells Companies

The following key companies have been profiled for this study on the cancer stem cells market:

• Thermo Fisher Scientific, Inc.

• AbbVie, Inc.

• Merck KGaA

• Bionomics

• Lonza

• The Menarini Group

• Miltenyi Biotec

• PromoCell GmbH

• MacroGenics, Inc.

• OncoMed Pharmaceuticals, Inc.

• FUJIFILM Irvine Scientific

• STEMCELL Technologies.

• Sino Biological, Inc.

• Lineage Cell Therapeutics, Inc.

Recent Developments

• In October 2024, Eterna Therapeutics and Factor Bioscience entered into an exclusive licensing and collaboration agreement to develop induced pluripotent stem cell (iPSC)-based oncology therapies. The collaboration combines Factor Bioscience's cell reprogramming and gene-editing technologies with Eterna's stem cell platform to accelerate the development of next-generation stem cell-based cancer therapies, strengthening innovation in regenerative medicine and oncology.

Cancer Stem Cells Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cancer stem cells market report based on mode of action, cancer forms, and region.

• Mode of Action Outlook (Revenue, USD Billion, 2021 - 2033)

  • Targeted Cancerous Stem Cells (CSCs)

    • By Anti-CSC Therapeutics

      • Pathway Inhibitors

        • WNT Signaling Pathway

        • Hedgehog Signaling Pathway

        • Notch Signaling Pathway

        • Others

      • Surface Marker-based

      • Immuno-evasion & Targeting Tumor Microenvironment

      • Nanoparticle-based Therapies

      • Others

    • By Products

      • Cell-Culturing

      • Cell-Separation

      • Cell Analysis

      • Molecular Analysis

      • Others

  • Stem Cell-based Cancer Therapy

    • Autologous SC Transplant

    • Allogeneic SC Transplant

• Cancer Forms Outlook (Revenue, USD Billion, 2021 - 2033)

  • Breast

  • Blood

  • Lung

  • Brain

  • Colorectal

  • Pancreatic

  • Bladder

  • Liver

  • Others

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Arabia

    • South Africa

    • UAE

    • Kuwait